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Reduction in digitalis-associated postinfarction 
mortality with nadolol in conscious dogs 
Previously, we have demonstrated an increased incidence of lethal ischemic arrhythmias in 
postinfarction dogs with clinically observable serum digoxin concentrations, and a significant 
reduction in digitalis-related lethal ischemic arrhythmias after subacute left stellectomy. In the 
present study, the protective actions of acute beta-adrenoceptor blockade with nadolol, 1.0 
mg/kg administered intravenously immediately preceding the induction of posterolateral 
myocardial ischemia, were assessed in conscious dogs with recent, small anterior myocardial 
infarctions pretreated with digoxin, 0.0125 rng/kg/day intravenously, for 5 to 7 consecutive 
days (total n = 11). A cohort of postinfarction dogs pretreated with digoxin alone served as a 
control group (total n = 26). Pre vs postdigoxin electrophysiologic testing indicated reductions in 
myocardial refractoriness in ventricular noniinfarct and infarct zones in both treatment groups, 
whereas the administration of nadolol tendecd to reverse the reductions in ventricular 
refractoriness. Arrhythmia-related deaths in response to posterolateral myocardial ischemia were 
reduced from 12 of 20 (60%) in the digoxin control group to 2 of 10 (20%) in the 
digoxin + nadolol group (p = 0.039). Serum digoxin concentrations (1.29 -t 0.14 rig/ml vs 
1.39 + 0.24 rig/ml), underlying anterior myocardial infarct size (6.9 + 1.5% vs 4.6 -t 0.9% of left 
ventricle), and developing posterolateral myocardial infarct size (22.6 + 2.5% vs 17.5 + 3.6% of 
left ventricle) did not differ significantly between the digoxin and digoxin + nadolol groups. Acute 
beta-adrenoceptor blockade with nadolol appears to reduce digitalis-mediated ischemic 
postinfarction mortality, possibly because of a salutary increase in ventricular refractoriness. (AM 
HEART J 1988; 115:67.) 
Joseph J. Lynch, Ph.D., Jan M. Kitzen, Ph.D., Paul T. Hoff, B.A., and 
Benedict R. Lucchesi, Ph.D., M.D. Ann Arbor, Mich. 
The clinical use of digitalis in the setting of ischemic 
myocardial injury, including the potential for digi- 
talis to exacerbate ischemic arrhythmias and 
increase postinfarction mortality, rema.ins contro- 
versial.1-7 Previous experimental studies, predomi- 
nantly utilizing acute administrations and toxic 
doses of digitalis preparations, have demonstrated 
an enhanced myocardial sensitivity to the arrhyth- 
From the Department of Pharmacology, The University of Michigan 
Medical School. 
Supported by National Institutes of Health, Heart, Lung, and Blood 
Institute grants HL-35325 and HL-05806. 
Received for publication May 26, 1987; accepted Aug. 4, 1987. 
Reprint requests: Joseph J. Lynch, Ph.D., Department of Pharmacology, 
M6322 Medical Science Building I, The University of Michigan Medical 
School, Ann Arbor, MI 48109-0010. 
mogenic actions of digitalis in the presence of myo- 
cardial ischemia,s-lo and /or infarction.8t g, 11-14 A vari- 
ety of diverse experimental investigations, once 
again utilizing toxic cardiac glycoside dosing regi- 
mens to initiate ventricular arrhythmias, have iden- 
tified an important interaction between the direct 
effects of digitalis and the sympathetic nervous 
system in the genesis of arrhythmias.15-I* The afore- 
mentioned experimental evaluations taken together 
suggest that a greater appreciation for and evalua- 
tion of the potential interactions between digitalis 
and the activation of the sympathetic nervous sys- 
tem in the development and treatment of postin- 
farction arrhythmias may be warranted. 
Previously, this laboratory has described the iden- 
tification of postinfarction dogs at low risk for the 
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subsequent development of ischemia-related malig- 
nant ventricular arrhythmias via programmed ven- 
tricular stimulation testing.lg The “low-risk” con- 
scious postinfarction dog model has been used to 
demonstrate a significantly enhanced susceptibility 
toward the development of ischemia-related lethal 
ventricular arrhythmias in the presence of therapeu- 
tic serum concentrations of digoxin.20 Recently, the 
interruption of sympathetic neural influences to the 
left ventricle via the surgical extirpation of the left 
stellate ganglion 5 to 7 days preceding acute poste- 
rolateral ischemia has been shown to be efficacious 
in reducing the incidence of lethal ventricular 
arrhythmias in conscious postinfarction dogs with 
therapeutic serum digoxin concentrations.21 In the 
present study, the cardiac electrophysiologic effects 
and antiarrhythmic efficacy of acute beta-adrener- 
gic receptor blockade with nadolol are evaluated in 
conscious postinfarction dogs administered digoxin 
in a multiday dosing regimen to achieve therapeutic 
serum concentrations. 
METHODS 
Surgical preparation. Detailed methods for the surgical 
preparation and instrumentation of dogs with anterior 
myocardial infarction have been described previously.zo 
Briefly, male mongrel dogs (I4 to 22 kg) were anesthetized 
with intravenous sodium pentobarbital, 30 mg/kg, and the 
lungs were ventilated with room air. The left external 
jugular vein was cannulated for subsequent drug adminis- 
tration. After a left-sided thoracotomy was performed, the 
left anterior descending coronary artery (LAD) was isolat- 
ed at the tip of the left atrial appendage, and the left 
circumflex coronary artery (LCX) was isolated approxi- 
mately 1 cm from its origin. Anterior ischemic injury was 
produced by occlusion of the LAD by means of a snare 
formed from a loop of silicone rubber tubing passed 
through a polyethylene cylinder, followed by restoration 
of LAD blood flow in the presence of a critical stenosis of 
silk ligature after a period of 2 hours. 
During the surgical preparation, an epicardial bipolar 
electrode (1 mm diameter silver posts, 3 mm electrode 
separation) was sutured to the left atria1 appendage for 
pacing. A stainless-steel bipolar plunge electrode (5 mm 
length, 2 mm electrode separation) was sutured into the 
interventricular septum adjacent to the right ventricular 
outflow tract (RVOT) near the site of LAD occlusion for 
determination of the ventricular excitation threshold, 
ventricular refractory period, and for programmed ven- 
tricular stimulation. Two short (2 to 3 mm) stainless-steel 
bipolar electrodes were used for measurement of ventricu- 
lar activation times and for construction of ventricular 
strength-interval curves. One bipolar electrode was 
implanted into the distribution of the LAD immediately 
distal to the site of coronary occlusion (IZ, infarct zone), 
whereas the second bipolar electrode was implanted in the 
LCX distribution (NZ, noninjured, normal zone). Finally, 
the tip of a silver wire electrode was inserted through the 
wall and into the lumen of the proximal LCX for sub- 
sequent application of electrical current to produce 
LCX intimal injury and ensuing posterolateral ischemia. 
Silver disc electrodes were implanted subcutaneously 
for ECG monitoring, surgical incisions were closed, and 
the animals were allowed to recover from the surgical 
anesthetic. 
Entry criteria and experimental protocol. Dogs were 
returned to the laboratory 4 to 5 days after anterior 
myocardial infarction. Electrophysiologic testing and pro- 
grammed ventricular stimulation were performed while 
the animals were conscious and resting comfortably in a 
sling. Only dogs that were not susceptible to the initiation 
of either nonsustained or sustained ventricular tachycar- 
dia (VT) at baseline programmed stimulation testing were 
evaluated in the present study. Previous work in this 
laboratory has demonstrated that postinfarction dogs that 
are not responsive to initiation of VT at baseline testing 
are at very “low risk” for development of lethal ventricular 
arrhythmias in response to the subsequent development 
of posterolateral ischemia (i.e., ischemia at a site remote 
from previous myocardial infarction).lg 
Immediately after baseline electrophysiologic and pro- 
grammed stimulation testing, 11 dogs that were prepared 
for treatment with digoxin plus acute beta-adrenoceptor 
blockade with nadolol (DIG + NAD group) began treat- 
ment with digoxin (0.0125 mg/kg/day intravenously [La- 
noxin, Burroughs Wellcome CO, Triangle Park, N.C.], 
administered in the afternoon as an infusion via the 
jugular vein) for 5 to 7 consecutive days (mean 2 SEM 
treatment duration 5.8 ” 0.5 days). A previous investiga- 
tion has demonstrated this dosing regimen to achieve 
trough digoxin concentrations of approximately 1.0 to 1.6 
rig/ml after 4 days of treatment,*O After the digoxin 
treatment period, DIG + NAD dogs were subjected to 
repeat electrophysiologic study and programmed ventric- 
ular stimulation in the conscious state. Immediately 
thereafter, DIG + NAD dogs (n = 10) were given 1.0 mg/ 
kg nadolol intravenously, followed 30 minutes later by a 
postnadolol electrophysiologic study and the initiation of 
electrical current to the LCX intimal surface (see below). 
It is noteworthly that a previous experimental study has 
estimated the duration of significant beta-adrenoceptor 
blockade with a 0.5 mg/kg intravenous dose of nadolol to 
be at least 22 hours.22 Separate studies in this laboratory 
determined the duration of a significant attenuation of the 
chronotropic response to intravenous isoproterenol in 
conscious dogs treated with 1.0 mglkg intravenous nadolol 
to exceed 24 hours. 
In this report, the effect of DIG t NAD treatment on 
cardiac electrophysiologic parameters and ischemic post- 
infarction mortality are compared to the results obtained 
in a cohort of 26 postinfarction control dogs treated with 
digoxin alone (DIG). This cohort of DIG control animals is 
comprised of two separate groups of 14 and 12 digoxin- 
treated postinfarction dogs each, which have been 
described separately in previous reports.20~21 The surgical 
preparation, entry criteria, animal mass (17.1 F 0.4 kg 
and 17.8 t 0.5 kg), duration of digoxin treatment (6.2 +- 
0.5 and 6.5 + 0.3 days), and resulting serum digoxin 
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concentrations (1.47 + 0.19 and 1.23 -t 0.14 :ng/ml) do not 
differ between the two groups comprising the DIG control 
group or among the digoxin controls group and the 
DIG + NAD group. 20,21 Repeat electrophysiologic study 
and programmed ventricular stimulation were performed 
in all DIG control dogs after digoxin treatment, after 
which electrical current to the LCX intimal surface was 
initiated in 20 DIG control dogs (see below). Technical 
failures associated with the induction of acute posterola- 
teral ischemia (fractured or improperly positioned LCX 
electrodes; n = 6 in DIG cohort and n = 1 in DIG + NAD 
group) account for the reduction in the numbser of animals 
developing posterolateral ischemia in the DIG and 
DIG + NAD groups. 
Electrophysiologic study and programmed ventricular 
stimulation. Animals were studied while they were con- 
scious and resting comfortably in a sling. ECG intervals 
and electrophysiologic parameters were determined 
immediately before programmed ventricular stimulation. 
ECG intervals, including a rate-corrected QT interval 
(QT, = QT in milliseconds/[R-R in seconds]!h) were mea- 
sured in sinus rhythm. A paced QT interval was measured 
during atria1 pacing at 2.5 Hz. RVOT excitation threshold 
and refractory period, measured during programmed 
stimulation, and NZ and IZ ventricular activation times 
were measured during 2.5 Hz atria1 pacing. The RVOT 
excitation threshold was the minimum voltage required to 
produce a conducted ventricular impulse (V,) by means of 
a single ventricular extrastimulus (S,) and a 4 msec pulse 
duration delivered 300 msec after the R wave of the lead II 
ECG. The RVOT refractory period was the longest R-S, 
interval at which a 2 x RVOT threshold voltage stimulus 
of 4 msec pulse duration failed to elicit a V, response. NZ 
and IZ activation times, the intervals between the Q wave 
of the lead II ECG and the largest deflection of the local 
ventricular electrogram (Q-EG), were measured on a 
Tektronix model 5111 storage oscilloscope (Tektronix 
Inc., Portland, Ore.). 
NZ and IZ ventricular excitation thresholds, relative 
refractory period (RRP), and effective refractory period 
(ERP) were determined by the construction of ventricular 
strength-interval curves according to a modification of the 
method of Michelson et a1.,23 which has been described in 
detail previously. 2o Ventricular strength-interval curves 
were generated during 2.5 Hz atria1 pacing in the con- 
scious dogs. The strength-interval curves were con- 
structed by the introduction of single ventricu.lar extrasti- 
muli at alternately increasing current strengths and 
decreasing coupling intervals. During the generation of a 
curve, current strength for an extrastimulus was increased 
whenever a reduction in the coupling interval to the 
preceding complex was sufficient to render the tissue 
inexcitable. At each site, the excitation threshold was the 
minimum milliamperage required to elicit a Vz response 
by means of an extrastimulus introduced at a coupling 
interval of 300 msec from the preceding complex. The 
ERP was the longest coupling interval that failed to elicit 
a V, response at a current strength of 4 mA, whereas the 
RRP was the longest coupling interval along the strength- 
interval curve at which the current required to evoke a V, 
response increased above the diastolic excitation thresh- 
old by more than 0.025 mA for a 1 msec change in the 
coupling intervalzo, 23 
The pacing protocol for programmed ventricular stimu- 
lation was identical to that used by this laboratory in 
previous investigations. 2o Briefly, single (S,), double 
(S,S,), and triple (S,S,S,) premature ventricular extrasti- 
muli (4 msec pulse duration, 2x RVOT threshold voltage) 
were introduced into the interventicular septum near the 
RVOT during 2.5 Hz atria1 pacing or sinus rhythm. The 
basic (S&S, coupling interval was decreased from 350 
msec until (RVOT) refractoriness occurred, whereas the 
S,-S, and S,-S, coupling intervals ranged from 182 msec 
(5.5 Hz) to 125 msec (8.0 Hz). 
lschemia at a site remote from previous myocardial 
infarction: Left circumflex coronary artery intimal stimu- 
lation and injury. After the completion of post-treatment 
programmed ventricular stimulation and electrophysio- 
logic testing, an anodal direct current of 150 PA was 
applied to the intimal surface of the LCX via the previ- 
ously inserted silver wire electrode. The lead II ECG was 
recorded directly onto a Grass polygraph or was recorded 
at preset intervals by a programmable cardiocassette 
recorder. 
After completion of the experiment at 24 hours of 
electrical stimulation or after the development of lethal 
arrhythmias, the hearts were excised and thrombus mass 
within the LCX was determined after removal by careful 
dissection. The heart was cut into 1 cm thick transverse 
sections that were incubated in 0.5 % triphenyltetrazolium 
chloride in 0.01 mol/L phosphate buffer (pH 7.4). Reac- 
tion with triphenyltetrazolium forms a red precipitate in 
viable tissue, whereas infarcted tissue remains pale.24*25 
Infarct size was quantitated gravimetrically and was 
expressed as a percentage of total left ventricle. 
Determination of serum ion and digoxin concentra- 
tions. Blood samples were obtained from all digoxin- 
treated animals immediately before postdigoxin treat- 
ment electrophysiologic and programmed stimulation 
testing. The blood samples were obtained by peripheral 
venipuncture approximately 16 hours after the pre- 
ceding administration of digoxin. Serum sodium and 
potassium concentrations were determined by flame 
photometry. Serum digoxin concentrations were deter- 
mined by means of radioimmunoassay technique in the 
Ligand Assay Laboratory of The University of Michigan 
Medical School, with the use of sheep antidigoxin antise- 
rum. 
Statistical analysis. Data are expressed as mean + 
SEM. Within the DIG control group, pre vs post- 
treatment comparisons were made by means of a two- 
tailed, paired Student’s t test. Within the DIG + NAD 
group, comparisons among predigoxin, postdigoxin, and 
postnadolol values were made by means of a repeated- 
measures analysis of variance, followed by Dunnett’s test 
for multiple comparisons. Differences between the DIG 
and DIG + NAD groups were analyzed by two-tailed, 
unpaired Student’s t test or by Fisher’s exact test, when 
appropriate. For aI1 comparisons, a p value of less than 
0.05 was the criterion for statistical significance. 
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Table I. Heart rate, ECG intervals, and electrophysiologic 
parameters for Digoxin control group 
Parameter* and Site Before After 
Sinus heart beat (bpmj 117 * 4 113 zk 5 
PR interval (msec) 115 rf: 3 117 f 3 
QRS interval (msec) 59 f 1 57 f 1t 
QT, interval (msec)/(sec)-” 286 f 4 265 k 4$ 
QT interval (msec) 198 + 4 187 f 2s 
Right ventricular outflow tract 
Threshold voltage (V) 2.0 * 0.2 2.4 + 0.2 
Ventricular refractory 158 rt 3 132 f 411 
period (msec) 
Noninfarct zone 
Excitation threshold (mA) 0.37 * 0.02 0.48 + 0.07 
Relative refractory period 165 f 4 147 * 3$ 
(msec) 
Effective refractory period 135 + 5 115 t 51 
(msec) 
Activation time (msec) 15.2 i 1.6 16.2 f 2.0 
Infarct zone 
Excitation threshold (mA) 0.47 i- 0.04 0.69 f 0.12t 
Relative refractory period 177 * 5 139 f 4/l 
(msec) 
Effective refractory period 150 * 5 115 t q\ 
(msec) 
Activation time (msec) 19.6 + 1.8 17.6 f 1.6 
*Heart rate, ECG, and noninfarct zone parameters n = 24 to 28, infarct 
zone parameters n = 20. 
fp < 0.05 compared to “before” value (Student’s paired t test). 
$p < 0.001 compared to “before” value (Student’s paired t test). 
§p < 0.01 compared to “before” value (Student’s paired t test). 
&I < 0.001 compared to “before” value (Student’s paired t test). 
RESULTS 
A total of 37 conscious postinfarction dogs were 
evaluated in the present study. All animals failed to 
respond to baseline programmed ventricular stimu- 
lation with either nonsustained or sustained VT in 
accordance with the entry criteria for this study. 
After baseline electrophysiologic testing, 26 control 
postinfarction animals (17.4 + 0.3 kg) were admin- 
istered 0.0125 mg/kg/day intravenous digoxin for 
6.5 -t 0.3 consecutive days, followed by repeat elec- 
trophysiologic testing and the initiation of acute 
posterolateral ischemia at a site remote from previ- 
ous anterior infarction (DIG control group). Eleven 
postinfarction dogs (17.5 +- 0.8 kg) were adminis- 
tered 0.0125 intravenous digoxin for 5.8 4 0.5 con- 
secutive days, followed by postdigoxin electrophysi- 
ologic study. Intravenous nadolol, 1.0 mg/kg, was 
then given to the latter 11 postinfarction dogs, 
followed by postnadolol electrophysiologic study 
and the initiation of acute posterolateral ischemia 
(DIG + NAD group). The responses of the DIG 
control and DIG + NAD dogs to electrophysiologic 
testing and to the subsequent development of acute 
posterolateral ischemia are summarized below. 
Response to programmed ventricular stimulation. ./?d 
DIG control and DIG + NAD postinfarction dogs 
entered into the evaluation were nonresponsive to 
baseline programmed stimulation. At the time of 
postdigoxin repeat programmed ventricular stimu- 
lation testing, DIG control dogs had a serum digoxin 
concentration of 1.33 2 0.12 rig/ml (n = 26), where- 
as DIG + NAD dogs had a serum digoxin concentra- 
tion of 1.30 + 0.23 rig/ml (n = 11). Postdigoxin pro- 
grammed stimulation failed to initiate nonsustained 
or sustained ventricular tachycardia in 25 of 26 DIG 
dogs and in 11 of 11 DIG + NAD dogs. One DIG 
control dog responding to postdigoxin programmed 
stimulation with rapid VT degenerating into ven 
tricular fibrillation possessed a relatively high serum 
digoxin concentration (2.69 rig/ml) and a very large 
underlying anterior myocardial infarction (17.9% of 
left ventricle). The cumulative anterior myocardial 
infarct sizes for the two treatment groups at the time 
of postdigoxin electrophysiologic study and pro- 
grammed stimulation were (percent of left ventri- 
cle): DIG + NAD, 4.7 + 0.8%; DIG 7.5 + 1.3% ; 
p = NS). 
Electrophysiologic responses. ECG and electro- 
physiologic parameters were determined at baseline 
testing and after digoxin treatment in DIG control 
dogs and DIG + NAD dogs, and after the acute 
intravenous administration of 1.0 mg/kg nadolol in 
DIG -i- NAD dogs. Tables I and II summarize the 
responses of the DIG and DIG + NAD groups to 
their treatments, respectively. 
The administration of digoxin to the cohort of 
DIG control dogs was characterized primarily by 
reductions in both the rate-corrected QT, and paced 
QT intervals, and by decreases in refractoriness 
determined in the normal NZ, “border zone” RVOT, 
and the IZ of the left ventricle. A previous evalua- 
tion of temporally matched, vehicle-treated postin- 
farction dogs has demonstrated that the observed 
reductions in ventricular refractoriness are attribut- 
able, at least in part, to electrophysiologic changes 
associated with infarct healing.20 In contrast to the 
findings obtained in vehicle-treated animals, howev- 
er, the administration of digoxin to postinfarction 
animals is characterized by a relatively enhanced 
reduction in both RRP and ERP in the IZ compared 
to the NZ, such that reductions in the RRP and ERP 
in the IZ attain a higher degree of statistical signifi- 
cance and no marked differences between the NZ 
and IZ are observable for either RRP or ERP after 
digoxin treatment (Table I). 
The ECG and electrophysiologic consequences of 
digoxin administration to DIG + NAD postinfarc- 
tion dogs were similar to th.ose observed in the DIG 
cohort (Table II). The decreases in T, and paced 
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Table II. Heart rate, ECG intervals, and electrophysiologic parameters for Digoxin + Nadolol group 
Parameter* and Site Before After digoxin 
Sinus heart rate (bpm) 130 i 8 115 * 9 
PR interval (msec) 109 f 3 115 + 4 
QRS interval (msec) 57 * 1 58 + 1 
QTc interval (msec)/(sec)-” 293 + 7 261 + 5t 
QT interval (msec) 192 _+ 6 167 k 7 
Right ventricular outflow tract 
Threshold voltage (V) 2.3 + 3.2 3.2 f  0.2t 
Ventricular refractory period (msec) 155 i 7 126 k ql 
Noninfarct zone 
Excitation threshold (mA) 0.40 * 0.03 0.69 +- 0.19 
Relative refractory period (msec) 163 f  6 149 f  4jj 
Effective refractory period (msec) 133 f  5 116 zk 7 
Activation time (msec) 5.4 If: 1.1 7.9 * 1.7 
Infarct zone 
Excitation threshold (mA) 0.81 zk 0.29 1.1 + 0.3 
Relative refractory period (msec) 171 f  9 149 f  67 
Effective refractory period (msec) 146 + 8 114 f  st 
Activation time (msec) 9.7 IL 2.4 11.4 f  1.8 
*Heart rate, ECG, right ventricular outflow tract, and noninfarct zone parameters n = 11; infarct zone parameters n = 10. 
tp < 0.01 compared to “before” value (Dunnetts test). 
& < 0.05 compared to postdigoxin value (Dunnetts test). 
sp < 0.01 compared to postdigoxin value (Dunnetts test). 
lip < 0.05 compared to “before” value (Dunnetts test). 
After nadolol 
94 + St-,$ 
132 + 4t,g 
59 It 1 
257 F St 
196 f  7 
- 
- 
0.71 k 0.24 
157 + 5 
121 + 8 
9.1 + 2.111 
1.1 4 0.3 
159 + 6 
121 i 87 
14.2 i 2.8 
Table III. Response to ischemia at a site remote from previous infarction 
Parameter 
Serum digoxin concentration (rig/ml) 
Duration of digoxin treatment (days) 
Time to posterolateral ischemia (min) 
A Heart rate with ischemia (percentage of preischemic rate) 
Myocardial infarct size (percentage of total left ventricle) 
Anterior infarction 
Posterolateral infarction 
LCX thrombus mass (mg) 
24-Hour mortality rate 
*p = 0.039 comparing mortality for digoxin + nadolol group vs digoxin group. 
Digoxin (n = 20) 
1.29 z!z 0.14 
6.2 + 0.4 
352 k 40 
25 k 5 
6.9 + 1.5 
22.8 zk 2.5 
14 * 3 
12/20 (60 % ) 
Digoxin + nadolol 
(n = 10) 
1.39 + 0.24 
5.8 t 0.5 
287 2 53 
19 k 10 
4.6 k 0.9 
17.4 -1- 3.6 
30 k 12 
2/10 (20%)* 
QT intervals, RVOT refractory period, and RRPs 
and ERPs in the NZ and IZ were quantitatively 
similar between the DIG + NAD and DIG groups, 
although the changes observed in the former group 
achieved a lower degree of statistical significance 
because of the lower sample size. The subsequent 
administration of nadolol to digoxin-treated postin- 
farction dogs resulted in a significant reduction in 
sinus heart rate and a prolongation in the PR 
interval. Administration of nadolol also partially 
reversed the decreases in the RRPs and ERPs of the 
NZ and IZ observed after treatment with digoxin 
(Table II). 
Response to ischemia at a site remote from previous 
myocardial infarction. An anodal current of 150 /IA 
was applied to the intimal surface of the proximal 
LCX in 20 DIG and 10 DIG + NAD postinfarction 
dogs immediately after postdigoxin and postnadolol 
repeat electrophysiologic studies, respectively. LCX 
intimal stimulation resulted in intimal injury, 
thrombus formation, and the ensuing development 
of posterolateral ischemia in the 20 DIG and 10 
DIG + NAD dogs evaluated. Technical failures asso- 
ciated with the placement of the LCX stimulating 
electrode (see Methods) account for the reduction in 
the r value for the treatment groups evaluated in the 
present phase of the study. At the initiation of 
intimal stimultion of the LCX, the serum digoxin 
concentrations in the 20 DIG and 10 DIG + NAD 
postinfarction dogs were 1.29 i 0.14 rig/ml and 
1.39 k 0.24 rig/ml (p = NS), respectively. Serum 
potassium and sodium concentrations for the 
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Fig. I. Mortality rates for digoxin- and digoxin + nadolol-pretreated postinfarction dogs after develop- 
ment of posterolateral myocardial ischemia subsequent to LCX injury and thrombosis. 
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Fig. 2. Cumulative mortality rates for postinfarction dogs pretreated with digoxin, digoxin -+ nadolol, 
vehicle,20 and digoxin in presence of subacute left stellate ganglion ablation,21 in response to development 
of posterolateral myocardial ischemia and infarction. 
DIG + NAD dogs were 4.02 + 0.02 and 119.5 i 2.8 
mEq/L, respectively, and are similar to values 
reported previously for digoxin-treated postinfarc- 
tion dogs.20, 21 
The responses of DIG and DIG + NAD animals to 
the development of posterolateral &hernia at a site 
remote from previous myocardial infarction are 
summarized in Table III. The durations of LCX 
intimal stimulation required for ECG manifestation 
of posterolateral ischemia, the increases in heart 
rate observed at the onset of posterolateral ischemia, 
and the sizes of underlying anterior myocardial 
infarctions did not differ between the DIG and 
DIG + NAD groups. The 24-hour ischemic postin- 
farction mortality rate was reduced significantly 
from 12 of 20 (60%) in the DIG control cohort to 2 of 
10 (20 % ) in the DIG + NAD group bp = 0.039). In 
the DIG group, seven arrhythmia-related deaths 
were characterized as ventricular fibrillation occur- 
ring “suddenly” (i.e., within 60 minutes) after tbe 
development of acute posterolateral ischemia, 
whereas the remaining five DIG deaths were due to 
ECG-verified ventricular fibrillation occurring dur- 
ing the “delayed” phase of automatic dysrhythmias 
that developed hours after the onset of acute poste- 
rolateral ischemia. The two arrhythmic deaths in the 
DIG + NAD group were due to ventricular fibrilla- 
tion developing suddenly after the onset of postero- 
lateral ischemia. Fig. 1 graphically depicts postin- 
far&ion mortality as a function of the duration of 
Volume 115 
Number 1, Part 1 Nadolol and postinfarction mortality ~3 
posterolateral ischemia for the DIG and 
DIG + NAD dogs in the present study. Fig. 2 com- 
pares the ischemic postinfarction mortality rates for 
DIG and DIG + NAD dogs in the present study to 
the ischemic mortality rates for postinfarction dogs 
treated with vehicle alonezo or with digoxin in the 
presence of left stellate ganglion ablation.21 The 
reduction in the ischemic postinfarction mortality 
rate attained in the DIG + NAD group relative to 
the DIG cohort is similar to those observed in the 
vehicle-treatment and digoxin + stellect.omy groups 
reported previously.zo*21 
Posterolateral myocardial infarct sizes deter- 
mined in “delayed” arrhythmic deaths and in 24- 
hour survivors did not differ significantly between 
the DIG and DIG + NAD groups (22.8 t- 2.5 and 
17.4 +- 3.6% of left ventricle, respectively), suggest- 
ing that the enhanced ischemic postinfarction sur- 
vival observed in the DIG f NAD group was not 
due to a significant reduction in the severity of the 
posterolateral ischemic insult. Posterolateral myo- 
cardial infarct sizes could not be determined in 
animals developing “sudden” ventricular fibrillation 
in response to acute posterolateral ischemia because 
of the lack of time available for the development of 
histochemical or morphologic evidence of cell death 
and tissue necrosis in the ischemic area.24 All DIG 
and DIG + NAD animals surviving 24 hours of 
ischemia in the LCX distribution developed second- 
ary posterolateral myocardial infarctions and dis- 
played a near 100 % frequency of ventricular ectopic 
complexes, but were otherwise stable. The mass of 
thrombus recovered at the site of LCX intimal 
injury in all dogs who died of arrhythmia and in 
survivors tended to be greater in DIG + NAD vs 
DIG animals, probably reflecting the enhanced 24- 
hour survival noted in the DIG + NAD group, allow- 
ing for a longer time for thrombus formation (Table 
III). 
DISCUSSION 
Despite their long-standing use in the inotropic 
support of the failing heart, the administration of 
cardiac glycosides in the setting of ischemic myocar- 
dial injury, and in particular their potential to 
exacerbate arrhythmias and increase postinfarction 
mortality, is controversia1.1-7 It is well established 
that the direct pharmacologic actions of cardiac 
glycosides include, in addition to cardiotonic activi- 
ty, the facilitation of transient inward ionic currents 
and the formation of delayed afterdepolarizations 
and “triggered activity”-type arrhythmias,26*27 as 
well as a partially direct coronary vasoconstrictor 
activity28 that might contribute to a worsening of 
ischemic injury and arrhythmia. Numerous experi- 
mental evaluations have demonstrated significant 
reductions in the intravenous and/or intracoronary 
letha18B l1 and arrhythmogenicg, lo, 12-14 threshold dos- 
ages for digitalis preparations during acute myocar- 
dial ischemia and after myocardial infarction in 
vivo. The clinical relevance of the latter findings has 
been questioned, however, because of the use of 
acute and rapid administrations of clearly supra- 
therapeutic and toxic concentrations of digitalis 
preparations in assessing myocardial sensitivity in 
the setting of ischemic myocardial injury. Recently, 
Hariman et al.,2g using microelectrode recording 
techniques in canine ischemic Purkinje fibers 
removed from l-day-old myocardial infarctions, 
demonstrated an increase in the magnitude of 
delayed afterdepolarizations and a sustainment of 
“triggered activity”-type arrhythmias in ischemic 
preparations exposed to the cardiac glycoside oua- 
bain at a concentration that caused no toxic effect in 
normal preparations. Lukas and Ferrier,30 who also 
used microelectrode recordings from canine isolated 
Purkinje fiber preparations, have reported that the 
“reperfusion” of the preparations after exposure to 
an “ischemic” buffer solution results in a potentia- 
tion of oscillatory afterpotential-induced arrhyth- 
mias in the presence of a subthreshold concentration 
of the cardiac glycoside acetylstrophanthidin. The 
latter in vitro studies support the concept of an 
enhancement of myocardial sensitivity toward the 
arrhythmogenic effects of cardiac glycosides in the 
setting of ischemic injury. 
The findings of numerous experimental studies 
indicate that many of the cardiovascular effects of 
the cardiac glycosides, including effects on cardiac 
conduction and, in part, coronary vasoconstriction, 
are modulated or affected by the autonomic nervous 
system.15, 18,31-33 A variety of experimental observa- 
tions have been cited as evidence for an interaction 
between direct drug effects and an activation of the 
sympathetic nervous system in the genesis of digital- 
is-induced arrhythmias.15-1s,31 These observations 
include: (1) an increase in sympathetic nerve fiber 
activity to the heart in the presence of arrhythmo- 
genie concentrations of cardiac glycosides34-37; (2) an 
attenuation of digitalis-induced arrhythmias and/or 
an increase in the arrhythmogenic threshold dosage 
of digitalis after cardiac denervation33, 38-40 or spinal 
cord/central nervous system transections”1f41-43 and 
(3) a reduction in the electrical threshold for hypo- 
thalamic stimulation to cause arrhythmias in the 
presence of the cardiac glycoside ouabain.44 Recently, 
Hewett and Rosen32 evaluated the interaction be- 
tween the direct electrophysiologic effects of cardiac 
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glycosides and adrenergic receptor stimulation in 
canine isolated Purkinje fibers. In the in vitro cardiac 
muscle preparations, it was shown that beta-adreno- 
ceptor stimulation enhanced delayed afterdepolari- 
zation amplitude and triggered activity in the pres- 
ence of the cardiac glycoside ouabain, whereas 
alpha-adrenoceptor agonists and antagonists had no 
effect.32 The latter findings suggest that the arrhyth- 
mogenic interaction between cardiac glycosides and 
sympathetic nervous system activity may be medi- 
ated primarily via beta-adrenergic receptor activa- 
tion. This mechanism may assume enhanced impor- 
tance in the setting of myocardial ischemia, during 
which increased neural sympathetic reflex activity5 
and local catecholamine re1ease46*47 occur. 
Recent investigations in this laboratory have 
focused on the effect of clinically relevant serum 
digoxin concentrations, achieved by multiday intra- 
venous dosing regimens, on the frequency and sever- 
ity of experimental ischemic ventricular arrhyth- 
mias, and on developing myocardial infarction. In 
conscious dogs without previous myocardial infarc- 
tion, the development of acute posterolateral ische- 
mia in the presence of clinically observable serum 
digoxin concentrations resulted in the evolution of 
significantly larger posterolateral myocardial infarc- 
tions and the occurrence of postinfarction ventricu- 
lar ectopic activity that was less sensitive to suppres- 
sion with conventional antiarrhythmic therapy, as 
compared to control animals that had not received 
digoxin pretreatment. 48 A previous report from this 
laboratory has described the identification of dogs in 
the subacute phase of anterior myocardial infarction 
that are at low risk for subsequent development of 
ischemic ventricular fibrillation via programmed 
ventricular stimulation testing.lgIn this “low-risk” 
postinfarction dog preparation, the administration 
of digoxin for the achievement of clinically relevant 
serum concentrations has been associated with a 
relatively enhanced reduction in ventricular refrac- 
toriness in infarcted tissue and a significant increase 
in the rate of postinfarction arrhythmic mortality 
occurring in response to posterolateral myocardial 
ischemia.20 Subsequently, Nelson et a1.21 have dem- 
onstrated that an interruption in sympathetic neu- 
ral input to the ischemically injured left ventricle is 
effective in reducing the incidence of ischemic lethal 
ventricular arrhythmias in postinfarction dogs. In 
the latter study, the surgical extirpation of the left 
stellate ganglion in “low-risk” digitalized postinfarc- 
tion dogs 5 to 7 days before the development of 
acute posterolateral ischemia reduced the incidence 
of ischemic arrhythmic death from 60% in sham- 
stellectomized, digitalis-treated animals to 10% in 
stellectomized, digitalis-treated anima1s.21 The 
latter findings suggest that a modulation of the sym- 
pathetic nervous system might reduce the ische- 
mic postinfarction mortality rate in the pres- 
ence of clinically relevant serum digoxin concentra- 
tions. 
The results of the present investigation support 
and extend the concept that a modulation of the 
sympathetic nervous system may be efficacious in 
reducing the incidence of digitalis-associated ische- 
mic arrhythmic death. In the present study, the 
acute administration of nadolol immediately before 
the initiation of LCX stimulation to produce poste- 
rolateral ischemia (i.e., nadolol administered 
approximately 4 to 6 hours preceding posterolateral 
ischemia) in digoxin-treated postinfarction dogs sig- 
nificantly reduced the incidence of ischemic 
arrhythmic death relative to digoxin-treated dogs 
that had not received nadolol. As noted previously, 
electrophysiologic studies have demonstrated de- 
creases in NZ and IZ ventricular refractoriness with 
infarct healing and digitalis administration in the 
conscious postinfarction canine preparation.20s21 The 
administration of digitalis in a therapeutic dosing 
regimen tends to enhance the decrease in refractori- 
ness preferentially in the IZ.20 In general, a decrease 
in ventricular refractoriness is thought to favor the 
initiation or perpetuation of reentrant arrhythmias 
by virtue of the establishment of more stable reen- 
trant circuits with functionally shorter wave- 
lengths.4g In contrast, the prolongation of ventricu- 
lar refractoriness is considered a salutary, potential- 
ly antiarrhythmic effect in that a slowing or termi- 
nation of reentrant arrhythmias may result from a 
lengthening of the wavelength of a reentrant cir- 
cuit.4s In the present study, the acute administration 
of nadolol to digitalis-treated postinfarction dogs 
resulted in a partial reversal of the observed 
decreases in the ventricular refractoriness of the NZ 
and IZ. The design of this study does not permit a 
clear determination of whether the effect of nadolol 
on ventricular refractoriness was a direct effect of 
the drug or secondary to a blunting of a digitalis- 
enhanced cardiac sympathetic neural tone. Previous 
studies have indicated that nadolol possesses mini- 
mal direct membrane effects,50g51 although a more 
recent study suggests that it may prolong ventricu- 
lar refractoriness via a class III electrophysiologic 
mechanism.52 Regardless of the mechanism, an 
increase in ventricular myocardial refractoriness 
with nadolol may have conferred, at least in part, 
some degree of antiarrhythmic protection in this 
paradigm. 
It may not be precluded that the protection 
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against ischemic postinfarction mortality observed 
with nadolol in the present study may have been due 
to some salutary drug action unrelated to the pres- 
ence of digitalis. Previous experimental antiarrhyth- 
mic evaluations have shown nadolol to be effective 
in suppressing ischemic ventricular arrhyth- 
mias,W 51% 53 presumably by virtue of its beta-adreno- 
ceptor-blocking activity. Conversely, it has been 
reported to be relatively ineffective in suppressing 
existing digoxin-induced arrhythmias in dogs50 It 
must be kept in mind, however, that the present 
“low-risk” postinfarction dog model possesses an 
inherently low rate of ischemic postinfarction death 
in the absence of digitalis, indicating at least a 
functional interaction between digoxin and nadolol 
in this preparation. Although it may be hypothe- 
sized that nadolol may have reduced ischemic post- 
infarction mortality in this study via a lessening in 
the severity of the ischemic myocardial insult, the 
lack of a significant difference between the sizes of 
developing posterolateral myocardial infarctions in 
“delayed” deaths and survivors in the DIG- and 
DIG + NAD-treated groups provides indirect evi- 
dence for similar degrees of ischemic insult. Finally, 
the conscious postinfarction dog model used in the 
present study, in which posterolateral ischemia is 
produced by electrical injury to the LCX and is 
followed by the occurrence of sudden lethal arrhyth- 
mias in a significant subset of animals, is not 
amenable to a controlled evaluation of the effect of 
nadolol treatment on regional myocardial blood 
flow. However, a salutary effect of nadolol on ische- 
mic blood flow might have been reflected, although 
not necessarily so, in a reduction in developing 
posterolateral myocardial infarct size. Regarding the 
potential effects of beta-adrenoceptor blockade on 
coronary blood flow in the present investigation, it is 
noteworthy that previous investigations have deter- 
mined the neurogenic coronary vasoconstrictor 
effects of digitalis, in the absence and presence of 
myocardial ischemia, to be mediated primarily via 
alpha-adrenoceptor activation.54p55 In contrast, pre- 
treatment with the beta-adrenoceptor antagonist 
propranolol has been shown to protect against the 
direct vasoconstrictor actions of the cardiac glyco- 
side ouabain and to reduce ensuing arrhythmias and 
cardiotoxicity in guinea pig isolated perfused 
hearts.56 
In summary, acute beta-adrenoceptor blockade 
with nadolol appears to be effective in reducing 
ischemic arrhythmic mortality in postinfarction 
dogs with clinically relevant serum digoxin concen- 
trations. A salutary increase in ventricular myocar- 
dial refractoriness may underlie, at least in part, the 
Nadolol and postinfarction mortality 75 
protective effects of nadolol in this setting, These 
findings support the concept that a modulation of 
sympathetic nervous system activity may be effec- 
tive in reducing digitalis-associated ischemic postin- 
farction mortality. 
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